COL4A3_HUMAN,G67S,0.919,Loss of Methylation at K63 (Pr = 0.18 | P = 0.01), ELME000064|ELME000136|ELME000146|ELME000159|ELME000220|PS00006,-
COL4A3_HUMAN,K78L,0.816,Gain of Loop (Pr = 0.29 | P = 9.6e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K78 (Pr = 0.27 | P = 1.2e-03); Loss of Acetylation at K78 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K78 (Pr = 0.19 | P = 0.05), ELME000005|ELME000155,-
COL4A3_HUMAN,F80S,0.070,-,-,-
COL4A3_HUMAN,T87M,0.114,-,-,-
COL4A3_HUMAN,T87R,0.219,-,-,-
COL4A3_HUMAN,S96T,0.035,-,-,-
COL4A3_HUMAN,E162G,0.083,-,-,-
COL4A3_HUMAN,E228D,0.085,-,-,-
COL4A3_HUMAN,M267I,0.063,-,-,-
COL4A3_HUMAN,V304I,0.060,-,-,-
COL4A3_HUMAN,I335T,0.087,-,-,-
COL4A3_HUMAN,T344I,0.302,-,-,-
COL4A3_HUMAN,P417S,0.529,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at P417 (Pr = 0.18 | P = 0.02), ELME000085|ELME000136|ELME000155|ELME000159|ELME000336|ELME000358,-
COL4A3_HUMAN,D450G,0.217,-,-,-
COL4A3_HUMAN,P639R,0.405,-,-,-
COL4A3_HUMAN,L737V,0.036,-,-,-
COL4A3_HUMAN,P837S,0.145,-,-,-
COL4A3_HUMAN,P903L,0.204,-,-,-
COL4A3_HUMAN,P905S,0.171,-,-,-
COL4A3_HUMAN,T911M,0.043,-,-,-
COL4A3_HUMAN,S917N,0.154,-,-,-
COL4A3_HUMAN,P918L,0.057,-,-,-
COL4A3_HUMAN,S948F,0.126,-,-,-
COL4A3_HUMAN,S1001R,0.106,-,-,-
COL4A3_HUMAN,R1063T,0.186,-,-,-
COL4A3_HUMAN,H1093Y,0.125,-,-,-
COL4A3_HUMAN,L1129F,0.019,-,-,-
COL4A3_HUMAN,G1143F,0.931,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), None,-
COL4A3_HUMAN,R1176G,0.104,-,-,-
COL4A3_HUMAN,K1206R,0.157,-,-,-
COL4A3_HUMAN,M1209K,0.319,-,-,-
COL4A3_HUMAN,R1215Q,0.074,-,-,-
COL4A3_HUMAN,A1285V,0.050,-,-,-
COL4A3_HUMAN,P1305L,0.037,-,-,-
COL4A3_HUMAN,K1339I,0.205,-,-,-
COL4A3_HUMAN,K1352Q,0.196,-,-,-
COL4A3_HUMAN,V1465A,0.109,-,-,-
COL4A3_HUMAN,L1541I,0.122,-,-,-
COL4A3_HUMAN,D1566N,0.150,-,-,-
COL4A3_HUMAN,A1599R,0.669,Gain of ADP-ribosylation at A1599 (Pr = 0.33 | P = 2.0e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Loss of Loop (Pr = 0.27 | P = 0.03), ELME000136|ELME000159,-
COL4A3_HUMAN,E1615N,0.814,Altered Metal binding (Pr = 0.41 | P = 6.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of Disulfide linkage at C1616 (Pr = 0.16 | P = 0.03), None,-
COL4A3_HUMAN,G1618S,0.812,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 8.5e-04); Loss of Strand (Pr = 0.26 | P = 0.05); Gain of Disulfide linkage at C1622 (Pr = 0.21 | P = 0.02), ELME000062|ELME000063|ELME000162,-
COL4A3_HUMAN,F1631H,0.820,Altered Ordered interface (Pr = 0.36 | P = 4.4e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered DNA binding (Pr = 0.26 | P = 5.3e-03); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Stability (Pr = 0.16 | P = 0.02), ELME000197,-
COL4A3_HUMAN,F1631K,0.922,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Helix (Pr = 0.29 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.27 | P = 3.7e-03); Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.22 | P = 0.01); Gain of Acetylation at F1631 (Pr = 0.19 | P = 0.05), ELME000197,-
COL4A3_HUMAN,S1635G,0.581,Loss of Helix (Pr = 0.30 | P = 9.2e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04), None,-
COL4A3_HUMAN,P1647A,0.211,-,-,-
COL4A3_HUMAN,A1652N,0.563,Altered Transmembrane protein (Pr = 0.21 | P = 4.2e-03), None,-
COL4A3_HUMAN,E1656V,0.504,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000333|ELME000335,-
COL4A3_HUMAN,K1657H,0.285,-,-,-
COL4A3_HUMAN,M1666T,0.684,Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Stability (Pr = 0.23 | P = 9.5e-03); Altered DNA binding (Pr = 0.18 | P = 0.03), PS00005,-
COL4A3_HUMAN,H1670V,0.283,-,-,-
COL4A3_HUMAN,Q182H,0.411,-,-,-
COL4A3_HUMAN,G1039R,0.937,Loss of Loop (Pr = 0.29 | P = 0.01); Altered Disordered interface (Pr = 0.25 | P = 0.02), ELME000012|ELME000101|ELME000102|ELME000108|ELME000155|ELME000231,-
COL4A3_HUMAN,G407C,0.920,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of SUMOylation at K403 (Pr = 0.26 | P = 6.5e-03); Loss of Acetylation at K411 (Pr = 0.25 | P = 0.01); Loss of Methylation at K411 (Pr = 0.19 | P = 7.8e-03); Gain of Disulfide linkage at G407 (Pr = 0.11 | P = 0.05), ELME000012,-
COL4A3_HUMAN,G584C,0.904,Loss of Acetylation at K583 (Pr = 0.32 | P = 3.0e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K583 (Pr = 0.24 | P = 3.0e-03), ELME000002,-
COL4A3_HUMAN,G49R,0.951,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of SUMOylation at K48 (Pr = 0.27 | P = 4.6e-03); Loss of Acetylation at K45 (Pr = 0.22 | P = 0.03); Loss of Methylation at K51 (Pr = 0.16 | P = 0.01), ELME000100|ELME000108,-
COL4A3_HUMAN,G634E,0.911,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at T629 (Pr = 0.15 | P = 0.04), ELME000155,-
COL4A3_HUMAN,G662E,0.927,Gain of Loop (Pr = 0.34 | P = 9.3e-04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G1242D,0.918,Gain of Loop (Pr = 0.29 | P = 9.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at R1247 (Pr = 0.19 | P = 8.6e-03); Loss of O-linked glycosylation at S1246 (Pr = 0.14 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1237 (Pr = 0.04 | P = 0.04), None,-
COL4A3_HUMAN,G1406E,0.929,Gain of Loop (Pr = 0.29 | P = 8.5e-03); Loss of Methylation at K1408 (Pr = 0.27 | P = 1.3e-03); Loss of Acetylation at K1408 (Pr = 0.26 | P = 9.5e-03); Gain of SUMOylation at K1408 (Pr = 0.26 | P = 6.7e-03); Gain of B-factor (Pr = 0.25 | P = 0.03), ELME000117,-
COL4A3_HUMAN,G608R,0.915,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of Methylation at G608 (Pr = 0.15 | P = 0.01), ELME000063|ELME000155|PS00005,-
COL4A3_HUMAN,G148V,0.936,Loss of Intrinsic disorder (Pr = 0.45 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at K153 (Pr = 0.17 | P = 0.01); Loss of Ubiquitylation at K153 (Pr = 0.17 | P = 0.02); Loss of Sulfation at Y143 (Pr = 0.01 | P = 0.05), PS00008,-
COL4A3_HUMAN,S1452C,0.692,Loss of O-linked glycosylation at T1455 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1453 (Pr = 0.11 | P = 8.2e-03), ELME000052|ELME000053|ELME000062|ELME000063|ELME000202,-
COL4A3_HUMAN,G1470W,0.910,Altered Transmembrane protein (Pr = 0.21 | P = 4.0e-03), ELME000063|ELME000085|ELME000120,-
COL4A3_HUMAN,G1334E,0.896,Gain of Loop (Pr = 0.29 | P = 9.7e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Acetylation at K1339 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1339 (Pr = 0.20 | P = 6.0e-03); Gain of SUMOylation at K1339 (Pr = 0.20 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G795V,0.951,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Loss of Methylation at R791 (Pr = 0.10 | P = 0.04), ELME000005|ELME000155,-
COL4A3_HUMAN,P879L,0.440,-,-,-
COL4A3_HUMAN,G91V,0.955,Loss of Acetylation at K90 (Pr = 0.25 | P = 0.01); Loss of Methylation at K90 (Pr = 0.20 | P = 6.8e-03); Gain of SUMOylation at K90 (Pr = 0.19 | P = 0.04); Gain of O-linked glycosylation at S96 (Pr = 0.13 | P = 0.04), ELME000336,-
COL4A3_HUMAN,G566A,0.936,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of SUMOylation at K565 (Pr = 0.21 | P = 0.03); Gain of Methylation at K565 (Pr = 0.17 | P = 9.1e-03), ELME000146|ELME000231,-
COL4A3_HUMAN,G1251S,0.884,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at R1247 (Pr = 0.18 | P = 9.3e-03); Gain of O-linked glycosylation at S1246 (Pr = 0.15 | P = 0.03), ELME000005|ELME000063|ELME000085|ELME000099|ELME000136|ELME000155|ELME000159,-
COL4A3_HUMAN,G1403R,0.914,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K1408 (Pr = 0.28 | P = 9.2e-04); Loss of Acetylation at K1408 (Pr = 0.27 | P = 7.2e-03); Gain of SUMOylation at K1408 (Pr = 0.20 | P = 0.03), ELME000136|ELME000159|ELME000358|PS00005,-
COL4A3_HUMAN,G801R,0.937,Loss of B-factor (Pr = 0.30 | P = 8.8e-03), ELME000135,-
COL4A3_HUMAN,G1319R,0.921,Gain of SUMOylation at K1318 (Pr = 0.32 | P = 2.5e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1321 (Pr = 0.27 | P = 7.8e-03); Loss of Methylation at K1318 (Pr = 0.15 | P = 0.01), ELME000002|ELME000100|ELME000108,-
COL4A3_HUMAN,G1488R,0.771,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), PS00008,-
COL4A3_HUMAN,G631R,0.932,Loss of O-linked glycosylation at T629 (Pr = 0.15 | P = 0.03), ELME000052|ELME000155|ELME000202|ELME000336|PS00005,-
COL4A3_HUMAN,G520R,0.945,Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of O-linked glycosylation at T519 (Pr = 0.13 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G695R,0.917,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000097|ELME000155,-
COL4A3_HUMAN,P574L,0.475,-,-,-
COL4A3_HUMAN,R1011C,0.187,-,-,-
COL4A3_HUMAN,R8G,0.127,-,-,-
COL4A3_HUMAN,L12F,0.078,-,-,-
COL4A3_HUMAN,P72L,0.305,-,-,-
COL4A3_HUMAN,G76W,0.944,Loss of B-factor (Pr = 0.32 | P = 3.6e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at K78 (Pr = 0.23 | P = 3.4e-03), ELME000080|ELME000155,-
COL4A3_HUMAN,V92A,0.141,-,-,-
COL4A3_HUMAN,G284R,0.299,-,-,-
COL4A3_HUMAN,Y350H,0.091,-,-,-
COL4A3_HUMAN,T358I,0.039,-,-,-
COL4A3_HUMAN,R365K,0.029,-,-,-
COL4A3_HUMAN,S382G,0.141,-,-,-
COL4A3_HUMAN,P394S,0.248,-,-,-
COL4A3_HUMAN,S402T,0.120,-,-,-
COL4A3_HUMAN,A423P,0.075,-,-,-
COL4A3_HUMAN,L428P,0.071,-,-,-
COL4A3_HUMAN,T519A,0.039,-,-,-
COL4A3_HUMAN,A610T,0.096,-,-,-
COL4A3_HUMAN,A635D,0.139,-,-,-
COL4A3_HUMAN,K681R,0.048,-,-,-
COL4A3_HUMAN,R832I,0.247,-,-,-
COL4A3_HUMAN,T835M,0.059,-,-,-
COL4A3_HUMAN,I860M,0.029,-,-,-
